Evidence map›Paper›PMID 26996442›Full record

Trial reportEuropean journal of clinical pharmacology2016

Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study.

Katja Cvan Trobec, Iztok Grabnar, Mojca Kerec Kos, Tomaz Vovk, Jurij Trontelj, Stefan D Anker, Giuseppe Rosano, Mitja Lainscak

Open access · greenAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Muscle wasting in heart failure : The role of nutrition.Wiener klinische Wochenschrift · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Katja Cvan TrobecFaculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Iztok GrabnarFaculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Mojca Kerec KosFaculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Tomaz VovkFaculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Jurij TronteljFaculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Stefan D AnkerInnovative Clinical Trials, Department of Cardiology and Pneumology, University Medical Center Göttingen (UMG), Göttingen, Germany.
Giuseppe RosanoCentre for Clinical and Basic Research, Department of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.
Mitja LainscakFaculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. mitja.lainscak@guest.arnes.si.
University of Ljubljana · SIIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversitätsmedizin Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe investigated bisoprolol pharmacokinetics, including longitudinal changes and importance of patient characteristics in chronic heart failure.

methodsForty-six patients with chronic heart failure (57 % male, NYHA class I/II/III = 2/36/8) were followed for an average of 8 ± 2 months. At baseline and follow-up, plasma bisoprolol concentrations were determined and body composition was measured using dual-energy X-ray absorptiometry. A bisoprolol pharmacokinetic model was built with non-linear mixed-effects modeling to analyze the association with various parameters of body composition.

resultsMean bisoprolol clearance (10.2 L/h) was 30 % lower than in healthy individuals and correlated with MDRD4-estimated renal function. The mean volume of distribution (230 L) was similar to healthy population and was associated with total body mass and skeletal muscle index (SMI). During follow-up, we observed minor changes in the absorption rate constant (2.83 vs. 2.27 h(-1), P = 0.030) and volume of distribution (227 vs. 250 L, P = 0.004), which are not clinically relevant.

conclusionsIn patients with chronic heart failure, bisoprolol clearance was associated with estimated renal function; thus, in moderately and severely decreased renal function, patients may need to have their dose adjusted. Patients with low body weight or low SMI have greater fluctuations and higher maximal plasma concentrations of bisoprolol because of the lower volume of distribution. Longitudinal changes of bisoprolol pharmacokinetics were not associated with changes in body composition.

Indexed as

Body CompositionAdrenergic beta-1 Receptor AntagonistsAgedAged, 80 and overBisoprololChronic DiseaseFemaleHeart FailureHumansKidneyMaleMiddle AgedModels, BiologicalAdrenergic beta-1 Receptor AntagonistsBisoprololBisoprololBody compositionCachexiaChronic heart failurePharmacokinetics

Identifiers

PMID26996442
OpenAlexW2305002767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.